Patients with solid tumors and RET-altered metastatic thyroid cancer who are two years of age or older are eligible to receive selercatinib.

Published Date: 02 Jun 2024

Patients two years of age and older with solid tumor, RET-altered metastatic thyroid cancer are eligible to receive selercatinib.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Short Shrift in Cancer Funding; Bypassing Familiar for Distant; Testing for BRCA.

2.

Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.

3.

Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap

4.

Novel topical fluorescent imaging technique rapidly and safely detects basal cell carcinoma

5.

Potential new therapy for childhood brain cancer could heal treatment-resistant tumors


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot